Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 19/20 | 0.69 |
| ▸ | LY96 | Q9Y6Y9 | 6/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6567647 | 1.00 | TLR4 (0.69) | TLR4LY96 | |
| SCHEMBL10611580 | 0.95 | TLR4 (0.64) | TLR4LY96 | |
| SCHEMBL9626318 | 0.90 | TLR4 (0.60) | TLR4LY96 | |
| SCHEMBL9626327 | 0.88 | TLR4 (0.57) | TLR4LY96 | |
| SCHEMBL3925341 | 0.87 | TLR4 (0.69) | TLR4LY96 | |
| SCHEMBL3938094 | 0.87 | TLR4 (0.69) | TLR4LY96 | |
| SCHEMBL3928509 | 0.87 | TLR4 (0.69) | TLR4LY96 | |
| SCHEMBL3937496 | 0.87 | TLR4 (0.69) | TLR4LY96 | |
| SCHEMBL3933640 | 0.87 | TLR4 (0.64) | TLR4LY96 | |
| SCHEMBL3925303 | 0.87 | TLR4 (0.64) | TLR4LY96 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1105401-B1 | PHOSPHOGLYCOLIPID AND METHODS FOR ITS USE | CORIXA CORP (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20020013291-A1 | Phosphoglycolipid and methods for its use | CORIXA CORPORATION | 2002-01-31 | — | — | US | disclosed |
| US-6013640-A | ANTIISCHEMIC AGENTS | RIBI IMMUNOCHEM RESEARCH, INC. (US) | 2000-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013291-A1 | Phosphoglycolipid and methods for its use | PYGL, GPI, PNLIP | TLR4 314/4885LY96 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.